Ballicules › Drugs › Iloperidone
What it is D2 and 5-HT2A antagonist antipsychotic; schizophrenia and bipolar mania.
Why it matters Akathisia and extrapyramidal effects are relatively uncommon.
What it changes Slow titration is required because of orthostatic hypotension, making it poor for acute agitation. QT prolongation; CYP2D6-dependent.
FDA-approved for
schizophrenia (2009) bipolar mania (2024)
FDA label
Read the full label on DailyMed ↗
BOXED WARNING Increased mortality in elderly patients with dementia-related psychosis.
FDA dosing Population Start Target Max
Schizophrenia Adults 1 mg BID 6–12 mg BID 12 mg BID
Schizophrenia — CYP2D6 poor metabolizers Adults 1 mg BID 3–6 mg BID 6 mg BID
Titration Increase daily per schedule over 7 days to target (to limit orthostatic hypotension)
Renal Undefined
Hepatic Mild (Child-Pugh A): no adjustment; moderate (B): may require dose reduction; severe (C): not recommended
Reinitiate titration if treatment interrupted >3 days
Instructions Take orally BID with or without food Reduce dose by one-half for CYP2D6 poor metabolizers and with strong CYP2D6 and/or CYP3A4 inhibitors If off drug >3 days, reinitiate with the initial titration schedule
Cautions QT prolongation — avoid with other QT-prolonging drugs Cerebrovascular reactions in elderly with dementia Neuroleptic malignant syndrome Tardive dyskinesia Metabolic changes (hyperglycemia, dyslipidemia, weight gain) Orthostatic hypotension/syncope Seizures Leukopenia/neutropenia/agranulocytosis Priapism Hyperprolactinemia
Adverse reactions Dizziness Dry mouth Fatigue Nasal congestion Orthostatic hypotension Somnolence Tachycardia Weight increased
Pregnancy Third-trimester exposure risks extrapyramidal and/or withdrawal symptoms in neonates
Lactation Do not breastfeed during treatment
⚠ BOXED WARNING
Increased mortality in elderly patients with dementia-related psychosis
Cost, est. cash $300–$2,500/month
Generic entry 2016
Classes and tags
Clinical profile
Therapeutic safety burden 2 / 4
Overdose danger 2 / 4
Weight-gain liability 2 / 4
Sedation liability 2 / 4
QT / Torsades 2 / 4
Direct muscarinic antagonism 0 / 4
Embryofetal risk 2 / 4
Legacy pregnancy category C
Defining liability Metabolic effects, extrapyramidal symptoms/tardive dyskinesia and agent-specific QT or orthostatic risk.
Active metabolites
Mechanism of action: Iloperidone ballicule
Open Iloperidone in the interactive console ↗
Memory aids: mascots and interaction avatars
“Fan napped (with) Eye opener” Antipsychotics are represented with spooky mascots Polka dots on pink → α1 blocker → syncope if titrated too quickly (hit the floor) The fan is napping (unplugged), not restless → low akathisia
Open Iloperidone in the interactive console ↗